- Home
- CERO vs UCAR Comparison
CERO vs UCAR Comparison
Compare CERO & UCAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- UCAR
- Stock Information
- Founded
- CERO 2017
- UCAR 2013
- Country
- CERO United States
- UCAR China
- Employees
- CERO N/A
- UCAR N/A
- Industry
- CERO
- UCAR Retail-Auto Dealers and Gas Stations
- Sector
- CERO
- UCAR Consumer Discretionary
- Exchange
- CERO Nasdaq
- UCAR Nasdaq
- Market Cap
- CERO 9.6M
- UCAR 8.8M
- IPO Year
- CERO N/A
- UCAR 2023
- Fundamental
- Price
- CERO $8.25
- UCAR $2.08
- Analyst Decision
- CERO Strong Buy
- UCAR
- Analyst Count
- CERO 2
- UCAR 0
- Target Price
- CERO $45.00
- UCAR N/A
- AVG Volume (30 Days)
- CERO 40.2K
- UCAR 85.1K
- Earning Date
- CERO 08-29-2025
- UCAR 10-07-2025
- Dividend Yield
- CERO N/A
- UCAR N/A
- EPS Growth
- CERO N/A
- UCAR N/A
- EPS
- CERO N/A
- UCAR N/A
- Revenue
- CERO N/A
- UCAR $6,067,871.00
- Revenue This Year
- CERO N/A
- UCAR N/A
- Revenue Next Year
- CERO N/A
- UCAR N/A
- P/E Ratio
- CERO N/A
- UCAR N/A
- Revenue Growth
- CERO N/A
- UCAR 124.09
- 52 Week Low
- CERO $6.71
- UCAR $1.74
- 52 Week High
- CERO $895.40
- UCAR $9.43
- Technical
- Relative Strength Index (RSI)
- CERO 49.24
- UCAR 38.54
- Support Level
- CERO $8.07
- UCAR $1.88
- Resistance Level
- CERO $8.90
- UCAR $2.05
- Average True Range (ATR)
- CERO 0.40
- UCAR 0.19
- MACD
- CERO 0.11
- UCAR 0.05
- Stochastic Oscillator
- CERO 59.38
- UCAR 58.62
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
About UCAR U Power Limited
U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.